Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Immunology
Reference39 articles.
1. Ahmadi H, Jamshidi AR, Mahmoudi M et al (2017) Hematological improvement of patients with active rheumatoid arthritis by β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property. Iran J Allergy Asthma Immunol 16:433–442
2. Ahmadi H, Jamshidi AR, Gharibdoost F et al (2018a) A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 26:737–745.
https://doi.org/10.1007/s10787-018-0475-z
3. Ahmadi H, Mahmoudi M, Gharibdoost F et al (2018b) Targeting of circulating Th17 cells by β-d-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology 26:57–65.
https://doi.org/10.1007/s10787-017-0410-8
4. Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581.
https://doi.org/10.1002/art.27584
5. Aletaha S, Haddad L, Roozbehkia M et al (2017) M2000 (β-d-mannuronic acid) as a novel antagonist for blocking the TLR 2 and TLR 4 downstream signalling pathway. Scand J Immunol 85:122–129.
https://doi.org/10.1111/sji.12519
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献